在急性前壁ST段升高心肌梗塞 (CODE-AAMI) 后,复合丹申滴液药丸对心室重塑和心脏功能的影响:随机安慰剂控制试验协议
Yu-Jie Wu1, Bo Deng1, Si-Bo Wang1
1Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Chinese journal of integrative medicine
|September 1, 2023
概括
化合物丹申滴剂 (CDDP) 可能改善心肌梗塞后的心脏功能. 这项研究评估了CDDP.
科学领域:
- 心脏病学 心脏病学
- 传统中国医药 传统中国医药
- 临床试验 临床试验
背景情况:
- 在急性前壁ST段升高心肌梗塞 (AAMI) 之后,心室重塑会导致心力衰竭和预后不佳.
- 优化治疗心室重塑至关重要.
- 化合物丹申滴液药 (CDDP) 显示出保护免受缺血-再输液损伤和减少心室重塑的潜力.
研究的目的:
- 评估CDDP在AAMI后改善心室重塑和心脏功能方面的疗效和安全性.
- 评估CDDP对更大的患者队列中心声学结果和临床事件的影响.
主要方法:
- 多中心,随机,双盲,安慰剂对照试验.
- 268名AAMI初级后皮肤冠状动脉干预 (pPCI) 患者被分配到CDDP或安慰剂组.
- 48周的随访评估了心声学参数 (LVEF,LVEDVI,LVESVI) 和二次终点 (NT-proBNP,心律失常,心血管事件).
主要成果:
- 心声图的结果包括左心室喷射分数 (LVEF),左心室终端透缩体积指数 (LVEDVI) 和左心室终端透缩体积指数 (LVESVI) 在48周.
- 在N-终端亲B型尿素 (NT-proBNP) 水平的变化.
- 节律失常和主要心血管不良事件的发生率.
结论:
- 这项研究将提供关于CDDP对AAMI患者的疗效和安全性的可靠数据.
- 积极的发现可以支持在AAMI管理中对CDDP的更广泛的临床建议.
- 该试验 (NCT05000411) 旨在确定CDDP作为一种可行的治疗选择.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.5K
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
8.3K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15